VORICONAZOLE
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
SLATE RUN PHARM
Drug class
Antifungal - Azoles Systemic
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections. Read more about Antifungal - Azoles Systemic
131 drugs in this class 79 manufacturers
Drugs in Antifungal - Azoles Systemic
TOLSURA (itraconazole)
ANTIFUNGALS-SYSTEMIC · CHRONIC PULMONARY HISTOPLASMOSIS ·+5
LIBERTAS PHARMA
VORICONAZOLE
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
VIONA PHARMACEU
VORICONAZOLE
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
SANDOZ
VORICONAZOLE
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
X-GEN PHARMACEU
VORICONAZOLE
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
SLATE RUN PHARM
VFEND IV (voriconazole)
ANTIFUNGALS-SYSTEMIC · DISSEMINATED CANDIDIASIS ·+6
Parke-Davis Pfizer
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC · PREVENTION OF DISSEMINATED CANDIDIASIS ·+2
PAR HEALTH USA,
POSACONAZOLE
ANTIFUNGALS-SYSTEMIC · PREVENTION OF DISSEMINATED CANDIDIASIS ·+2
Lannett Company
Filter & compare in the drug finder →
Opens the drug finder with Antifungal - Azoles Systemic preselected. Add indication or manufacturer filters there.
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections.
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth.
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts.
-
drugs.com
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazol...
-
researchgate.net
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections
-
nih.gov
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections
-
fungaleducation.org
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth
-
cdc.gov
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth
-
nih.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
-
fda.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
-
fda.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.